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The interferons (IFNs) are glycoproteins which
have, in addition to anti-viral activity, anti-
proliferative and immunomodulating properties
(Borden, 1979; Billiau, 1981). The latter two
suggested an anti-tumour potential for these
substances and IFN has now been used in the
treatment of a variety of malignant diseases. To
date, there have been no reports of its use in
human hepatocellular carcinoma (HCC). There is
considerable epidemiological, serological and
molecular biological evidence implicating the
hepatitis-B virus in the aetiology of HCC (Kew,
1981), and this provides an additional reason for
investigating the effects of IFN on the course of
this tumour. We report a pilot trial of recombinant
leucocyte alpha IFN (IFLrA; Hoffman la Roche) in
the treatment of HCC.
Sixteen patients with inoperable HCC were
entered in the trial (Table I). With one exception,
all were histologically proved. The exception (no.
16) was considered to have HCC on the basis of
the clinical findings and a serum alpha-foetoprotein
(AFP) concentration of 8 x 103ngml - (normal
<10). Five patients had a well-differentiated, 8 a
moderately-differentiated, and 2 a poorly-
differentiated tumour. A trabecular pattern was
present in 9 patients, a solid pattern in 3 and a
scirrhous pattern in 3. One patient had a clear cell
variant. The disease was confined to the liver in 13
patients and 3 had pulmonary metastases. All the
patients conformed to required inclusion criteria with
respect to haematological function (haemoglobin
> 10gdl-1, leucocyte count >3 x 1091- 1
granulocytes > 1091-1, platelets >30 x 1091-1)
and renal function (blood urea and creatinine levels
<2.5 times upper limit ofnormal). Although hepatic
function tests were abnormal, impairment was not
severe enough to exclude these patients from the
trial (prothrombin ratio >2.5 times normal was
considered to indicate severe hepatic impairment).
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None of the patients had a history of, or showed
obvious evidence for, cardiac or neurological disease.
Some had other diseases or abnormalities. No patient
had received prior radiotherapy or chemotherapy.
Ten patients showed markers of current hepatitis B
virus infection and 5 markers ofpast infection.
Patients were randomised into two treatment
groups: Eight received 12 x 106 units IFLrAm-2
body surface area by i.m. injection 3 times per week
(low dosage) and 8 50x 106 units m-2 i.m. 3 times
per week (high dosage). The drug was administered
for up to 12 weeks. The purpose and nature of the
trial was explained to the participants and their
consent obtained. The trial was approved by the
Therapeutics Committee of the Hillbrow Hospital
where it was conducted. Dosage reductions or
interruptions were made when necessary according
to a prescribed protocol. Blood transfusions were
administered when haemoglobin levels dropped
below I0gdlP1 in 4 patients (nos. 1, 2, 11, 13), and
after a haematemesis in one patient (no. 7). All
patients received analgesics as necessary and para-
cetamol for influenza-like symptoms associated with
IFN administration. Other appropriate medications
were given as required. No aspirin, non-steroidal
anti-inflammatory agents or corticosteroids were
permitted.
A complete remission was defined as dis-
appearance of all evidence of tumour; regression as
a definite decrease in tumour size determined by
two investigators; stable disease as no definite
increase or decrease in tumour size assessed by two
investigators; and progression as a definite increase
in tumour size or the appearance of a new lesion
agreed by two investigators.
Only 2 patients (nos. 5, 9) completed the 12 week
course of treatment (Table II). In patient no. 5 the
disease remained stable during this period, and she
has since received 4 further courses of IFLrA at the
same (low) dosage. The disease was slowly
progressive for 1 year after therapy was initiated
but in the past few months her condition has
deteriorated markedly and she has become deeply
jaundiced. Patient no. 9 showed progressive disease,
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but was still in a fair condition at the end of the
trial. He received a second course of the drug (high
dosage), but then requested repatriation. When sub-
sequently followed at a rural hospital he
complained of abdominal pain, and his condition
was noted to have deteriorated. He was still alive
14 months after the initiation of therapy. Four
patients (nos. 1-4) showed progressive disease which
was considered to be the direct cause of death.
Patient nos. 1, 2 and 4 were treated for 4, 5 and 10
weeks, respectively, before succumbing to their
disease. Treatment was stopped in patient no. 3
after 10 weeks when he developed pulmonary
metastases, and he died 2 weeks later. The disease
was also considered to be progressive in a further 9
patients (nos. 6, 7, 10-16). Five of these (nos. 6, 12,
14-16) were assessed as having died in part as a
result of tumour progression and in part because of
drug toxicity. Patient no. 6 received 5 weeks of
treatment with an interruption in week 2 because of
confusion, which settled off treatment and then
recurred with further treatment. He died after 5
weeks. Patient no. 12 died after receiving treatment
for 4 weeks. He had become confused and
developed seizures. Patient no. 15 also suffered
confusion after 1.5 weeks. He died a few days later.
Acute renal failure developed in patient nos. 14 and
16 after 3 and 1.5 weeks treatment, respectively.
Both died a few days later. Drug-related side effects
necessitated discontinuation of treatment in 3
patients (nos. 8, 11, 13). Patient no. 8 developed
cardiac failure after his initial dose of IFLrA and
therapy was not continued. He was later lost to
follow-up. Treatment was stopped in patient no. 11
when severe oro-pharyngeal candidiasis appeared
after 10 weeks of treatment. He died 7 weeks later
after showing rapidly progressive disease. Patient
no. 13 received treatment for 2 weeks. The drug was
stopped, after the patient developed a seizure and
she died 1 month later from disease progression.
Two patients (nos. 7, 10) requested early
repatriation. Patient no. 10 died 1 month after
discharge. He had received treatment for 2 weeks.
Patient no. 7 had received therapy intermittently
for 4 weeks (it was stopped because of a haema-
temesis), and he died 4 months after discharge.
The mean survival time from initiation of
treatment in the 13 patients who died was 7.9
weeks.
There was no specific pattern of serum AFP
concentrations, although the patient who entered
the study with a normal value had concentrations
above 400ngml' by 12 weeks of treatment.
None of the patients were shown to develop
antibodies against IFN at any stage of the study.
Treatment with IFLrA resulted in a number of
side effects (Table II). The 2 patients with grand
mal seizures did not have cerebral metastases or an
organic cerebral lesion at necropsy. Tolerance to
IFLrA can be summarised as follows: good (no
decrease in dose required) in 6 patients, fair
(decrease in dose or corrective treatment) in 3
patients, poor (drug permanently discontinued) in 7
patients.
The anti-tumour and immune-modulating effects
of IFN have been investigated in HCC, both in
vitro and in animal experiments. One study, using
PLC/PRF/5 cells, showed that these cells in tissue
culture did not produce endogenous IFN, but
exogenous IFN had a marked cellular inhibitory
effect (Desmyter et al., 1981). Neither human
leucocyte or fibroblast IFN exhibited a tumour-
inhibitory effect in nude mice injected with
PLC/PRF/5 cells (Desmyter et al., 1981). In another
study, anti-IFN antibody enhanced tumour growth
and invasiveness of PLC/PRF/5 cells (Shouval et
al., 1983).
Our trial showed little efficacy of IFLrA in 16
black patients with advanced HCC. Only 2 patients
completed the 12-week treatment period, one with
slowly progressive and the other with obviously
progressive disease. The former may have a less
fulminant, slower-growing type of HCC similar to
that observed in western patients and occasionally
encountered in black patients. The possibility exists
that indolent tumours may respond better to IFN
than aggressive malignancies. Of the remaining 14
patients, 13 showed rapidly progressive disease
culminating in death. Death was considered to be
the result of tumour progression alone in 6 patients,
and of combined tumour progression and drug
toxicity in 5 patients. Drug-related side effects
necessitated discontinuation of treatment in 3
patients, 2 of whom subsequently died of their
disease, and one patient was lost to follow-up.
Although the majority of the patients were of
high performance status when they entered the trial,
many of them deteriorated rapidly on therapy and
9 of the 16 received less than 4 weeks of treatment.
These patients clearly had advanced and rapidly
progressive disease and this raises the issue of
whether patients of this sort are suitable for a phase
II trial.
Numerous side effects have been described with
leucocyte IFN-ax, and they were frequently
encountered in the present study. One possible
reason for this may be elevated blood levels of the
drug consequent upon hepatic dysfunction, since
IFN is possibly metabolised in the liver (Desmyter
et al., 1981; Bocci, 1981). The possibility that
hepatic encephalopathy was precipitated by IFN
needs to be considered in relation to the neuro-
logical side effects. However, liver function was
usually good and none of the patients showed
obvious signs of hepatic pre-coma.
In conclusion, the results obtained in this pilot
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Table II Summary of treatment, side effects and response to treatment in the 16 patients
Interferon Length of
dose treatment
Patient (x 106um-2) Side effects (weeks) Tolerance Outcome Death and cause
1 12 Nausea with vomiting. Into 4th
Anorexia,
Weight loss.
Infection
2 50 Flue-like syndrome. Into 5th
Weight loss.
Paraesthesias.
Infection
3 12 Flu-like syndrome End of 10th
4 12 Pyrexia.
ECG changes
5 12 Weight loss
6 12 Neorological.
Flu-like syndrome
7 50 Thrombocytopenia+
haematemesis
Flu-like syndrome
8 50 Cardiac failure
syndrome
9 50 Flu-like syndrome.
Cardiac.
Intermittent neutropenia
10 50 Flu-like syndrome
11 12 Flu-like syndrome.
Intermittent neutropenia.
Nausea+vomiting.
Infection
12 50 Neorological
(including fits)
13 12 Neorological
(including fits).
Nausea+vomiting
14 12 Nausea+vomiting
Flu-like syndrome.
Renal failure.
Weight loss
15 50 Flu-like syndrome.
Neurological
16 50 Flu-like syndrome.
Renal failure
Into 10th
Fair Progressive disease 4 weeks due to disease
Good Progressive disease 5 weeks due to disease
Good Progressive disease 12 weeks due to disease
with lung secondaries
Good Progressive disease 10 weeks due to disease
Completed 12th Good Stable disease Still alive
Into 5th with stop Fair Progressive disease 5 weeks due to disease
for 2 doses at end and drug
2nd week
Into 4th. Stopped Fair Progressive disease Died 4 months after
for haematemesis stopping drug - due to
disease
1 dose only Bad No further follow-up
Completed 12th Good Progressive disease Still alive
Into 2nd Good Progressive disease Died 1 month after
treatment discontinued
End 10th week Bad Progressive disease Died 7 weeks after
treatment discontinued
due to disease
End of4th
End of 2nd
Into 3rd
Into 2nd
Into 2nd
Bad Progressive disease 4 weeks - due to drug
with lung secondaries Autopsy negative for
cerebral metastases
Bad Progressive disease Died 1 month after
treatment discontinued
due to disease.
Autopsy negative for
cerebral metastases
Bad Progressive disease 3 weeks due to disease
and drug
Bad Progressive disease 2 weeks due to disease
and drug
Bad Progressive disease 2 weeks due to disease
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trial of IFLrA were as disappointing as those which
have been achieved with other forms of cancer
chemotherapy in black patients with HCC. This is
not altogether unexpected as the tumours were
large and it is known that large tumours respond
poorly to IFN. We encountered significant drug
tocixity in these patients and this was not restricted
to the patients receiving the higher doses.
Nevertheless, IFN may possibly have a part to play
in the treatment of less advanced HCC or as an
adjuvant to other modes of treatment.
The authors are grateful to Hoffman La Roche (Pty.) Ltd.
for generous supplies of recombinant leucocyte IFN and
for financial assistance.
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